Vilanterol

Systematic (IUPAC) name
4-{(1R)-2-[(6-{2-[(2,6-Dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
Clinical data
Legal status	UK: POM (Prescription only) US: ℞-only ℞ (Prescription only)
Identifiers
CAS Number	503068-34-6
ATC code	R03AK10 (WHO) (+fluticasone) R03AL03 (+umeclidinium)
PubChem	CID: 10184665
ChemSpider	8360167
ChEBI	CHEBI:75037
Chemical data
Formula	C24H33Cl2NO5
Molecular mass	486.43 g/mol
SMILES c1cc(c(c(c1)Cl)COCCOCCCCCCNC[C@@H](c2ccc(c(c2)CO)O)O)Cl
InChI InChI=1S/C24H33Cl2NO5/c25-21-6-5-7-22(26)20(21)17-32-13-12-31-11-4-2-1-3-10-27-15-24(30)18-8-9-23(29)19(14-18)16-28/h5-9,14,24,27-30H,1-4,10-13,15-17H2/t24-/m0/s1 Key:DAFYYTQWSAWIGS-DEOSSOPVSA-N

Vilanterol (INN, USAN) is an ultra-long-acting β₂ adrenoreceptor agonist (ultra-LABA), which was approved in May 2013 in combination with fluticasone furoate for sale as Breo Ellipta by GlaxoSmithKline for the treatment of chronic obstructive pulmonary disease (COPD).

Vilanterol is available in following combinations:

• with inhaled corticosteroid fluticasone furoate — fluticasone furoate/vilanterol (trade names Breo Ellipta (U.S.), Relvar Ellipta (EU, RU))
• with muscarinic antagonist umeclidinium bromide — umeclidinium bromide/vilanterol (trade name Anoro Ellipta)

See also

• Salmeterol — a long-acting β₂ adrenoreceptor agonist (LABA) with a similar backbone.